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Pneumonectomy for Non-small Cell Lung Cancer
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Introduction: The aim of this study is to compare the outcomes of
sleeve lobectomy (SL) and pneumonectomy (PN) and to determine
which one is more acceptable standard procedure for patients with
non-small cell lung cancer.
Methods: From 1996 to 2005, 424 patients underwent SL (n  157)
and PN (n 267) in our institution. Propensity score matching analysis
was performed to compare these two groups for mortality, morbidity,
survival, recurrence, and postoperative pulmonary function.
Results: In each group, 105 patients were eligible for analysis. The
operative mortality was lower in the SL group (1.0%) than the PN
group (8.6%), (p  0.0001). The morbidity was similar (33.4%
versus 29.5%, p  0.376). The 5-year survival was lower in the PN
group (PN, 32.14% versus SL, 58.43%, p 0.0002). The recurrence
pattern (locoregional versus distant) did not differ between two
groups (p  0.180). The mean actual postoperative first second
forced expiratory volume in the patients underwent SL was 2.05 
0.55 liter, which increased by 7.9% compared with the predicted-
postoperative first second forced expiratory volume.
Conclusions: Our results showed that the SL can be performed with
low operative risk and may offer superior survival and better
postoperative pulmonary function compared with the PN in selected
patients. If anatomically feasible, a SL must be considered as a
favorable alternative to PN in patients with non-small cell lung
cancer.
Key Words: Non-small cell lung cancer, Sleeve lobectomy,
Pneumonectomy.
(J Thorac Oncol. 2010;5: 517–520)
Sleeve lobectomy (SL) was first introduced for patientswith lung cancer who were unable to tolerate a pneumo-
nectomy (PN) due to compromised lung function. Initially,
the SL was considered only as an alternative procedure,
because of the complex surgical technique and the possibility
of incomplete resections compared with the PN. Because
surgical experience with the SL accumulates, it has been
shown that the SL could offer a local tumor control and be a
safe operative modality.1–7 In addition, the PN is associated
with several serious medical problems.8,9 Nevertheless, de-
spite the SL is widely used at present, there are still some
debates on the efficacy of this procedure. Points to consider
include the following: whether to perform a SL in patients
with sufficient lung function, whether the operative procedure
is safe, whether the procedure is adequate as a cancer oper-
ation, and whether the reimplanted lung functions normally.
The objective of this retrospective study was to com-
pare the outcomes of the SL and PN, focusing on the
operative outcomes, recurrence, survival, and postoperative
functional aspects of these procedures and to determine
whether SL can be accepted as a favorable alternative pro-
cedure to PN for patients with non-small cell lung cancer
(NSCLC), not only in patients with pulmonary dysfunction
but also in patients with sufficient pulmonary function.
PATIENTS AND METHODS
There were 1973 consecutive patients with primary
NSCLC, who underwent major lung resection surgery from
1996 to 2005 in Samsung Medical Center, Seoul, Korea. Of
the 1973 patients, lobectomy/bilobectomy was performed in
76.6% (n  1511), PN in 14.9% (n  294), and SL in 8.5%
(n  168). Eleven patients who received sleeve PN were
excluded from study, and finally, 451 patients with PN or SL
were listed for analysis.
In our institution, cervical mediastinoscopy was rou-
tinely performed in patients with preoperative diagnosis of
lung cancer. The patients diagnosed with N2 disease by
mediastinoscopy underwent neoadjuvant chemoradiotherapy.
After that, restaging of local tumor extension and nodal status
were assessed to determine the operative procedures. The
predicted postoperative first second forced expiratory volume
(FEV1) was calculated using pulmonary function testing and
lung perfusion scintigraphy. Among 77 patients (49%) of the
patients with SL, the predicted post-PN FEV1 was compared
with the actual postoperative FEV1. Postoperative spirometry
was performed at a median of 3.9 months after the surgery
(mean: 9.8  11.2 months, range: 0.5–45.8 months). We
tried to perform SL whenever it was technically feasible in
patients who otherwise were candidates for PN, even if they
had sufficient functional pulmonary reserve. Sleeve resec-
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tions were performed in the right upper lobe (n  70), right
middle lobe (n  3), right lower lobe (n  8), right middle
lobe and right lower lobe (n  17), right upper lobe and right
middle lobe (n  9), the left upper lobe (n  40), and left
lower lobe (n  21). Concomitant pulmonary angioplasty
(bronchovascular sleeve resection) was done in 30 patients
(17.86%). Right PN was performed in 107 patients, and left
PN in 176. Combined procedures with PN included pericar-
dial resection (n 9), chest wall resection and reconstruction
(n  8), partial superior vena cava resection (n  2),
descending thoracic aorta replacement (n  2), partial pleu-
rectomy (n  2), diaphragm resection and reconstruction
(n  2), and partial resection of esophagus and left atrium
(n  1). For all operations, the resection margin of the
bronchus was confirmed intraoperatively, and routine system-
atic mediastinal lymph node dissection was carried out.
Histologic typing was performed according to the World
Health Organization classification. Surgical-pathologic stag-
ing was determined according to the New International Stag-
ing System for Lung Cancer (International Union Against
Cancer, 1997). Operative mortality was defined as any post-
operative death within 30 days and in hospital death. Post-
operative complications were subdivided into major compli-
cations, which included acute respiratory distress syndrome
(ARDS), bronchopleural fistula (BPF), bronchovascular fis-
tula, empyema, severe bronchial stenosis requiring comple-
tion PN, and chylothorax requiring reoperation. The minor
complications included pneumonia based on the chest radio-
graphic findings that required antibiotics, atelectasis, or bron-
chial stenosis that could be managed by therapeutic bronchos-
copy, vocal cord palsy, radiation pneumonitis, a persistent air
leak for more than 7 days, chyle leak, wound infection, and
cardiac problems that could be treated medically such as
atrial fibrillation and heart failure. Among the patients with
morbidity or mortality, anastomosis or bronchial stump-re-
lated complications including BPF, bronchovascular fistula,
atelectasis, and bronchial stenosis were subgrouped to deter-
mine the negative effects of the operative procedure itself. A
locoregional recurrence was defined as any recurrence in the
ipsilateral hemithorax such as bronchial stump or anastomo-
sis, ipsilateral remaining lobe, ipsilateral mediastinal lymph
nodes, or ipsilateral mediastinal structures. A distant recur-
rence was defined as any recurrence at distant organs or in the
contralateral lung.
All patients completed follow-up, and all the patients
(n  451) were included in the survival analysis. The fol-
low-up period ranged from 1 to 154 months, with a median of
30.73 months (mean: 41.8 36.7 months). The patients were
subdivided into two groups, SL group and PN group. To
create two comparable groups with common clinicopatho-
logic background, we performed propensity score analysis,
using nearest neighbor matching method of covariates, which
includes age, sex, neoadjuvant therapy, cell type, and patho-
logic stage of tumor. Other variables such as tumor size,
preoperative pulmonary function, and postoperative adjuvant
therapy were compared to verify that these two groups are
nearly identical for statistical comparison.
Statistical Analysis
Statistical analysis was performed using statistical soft-
ware (SAS, version 9.1.3). Data are reported as the mean 
standard deviation or as a proportion. Survival rates were
calculated according to the life-table (actuarial) method and
were compared between groups with the Wilcoxon test. Time
zero was the date of the operation. Other comparisons were
made using an unpaired t test or 2 test. A p value less than
0.05 was considered to be significant.
RESULTS
Clinical Characteristics
Comparisons of the patients’ clinical characteristics in
the SL and PN groups are shown in Table 1. By performing
nearest available pair matching, 105 patients in each group
were eligible for analysis. The match model was favorable for
analysis, i.e., area under the curve of receiver operating
characteristic curve was 0.74621, and p value was 0.7532 by
the Hosmer-Lemeshow test. All the covariates were well
balanced, and there were no significant difference in preop-
erative pulmonary function of patients and performance of
postoperative adjuvant treatment. Only the size of tumor was
significantly greater in the PN group compared with the SL
group (3.74 1.86 in SL group and 5.20 2.66 in PN group,
p  0.001).
TABLE 1. Comparison of Patient Characteristics: Sleeve
Lobectomy and Pneumonectomy
Sleeve
Lobectomy Pneumonectomy p
Number 105 105
Age (yr) 61.25  8.89 62.24  8.42 0.259
Gender (M/F) 99/6 98/7 0.439
Cell type
Squamous cell carcinoma 91 (77.7%) 89 (71.9%) 0.700
Adenocarcinoma 8 (10.2%) 11 (18.7%)
Large cell carcinoma 2 (2.5%) 3 (0.7%)
Othersa 4 (5.7%) 2 (3.4%)
p-Stage
IA/IB 4/40 2/41 0.920
IIA/IIB 2/30 3/33
IIIA/IIIB 19/7 17/7
IV 3 2
Neoadjuvant therapy
Chemotherapy 10 (9.52%) 10 (9.52%) 1.000
Radiotherapy 8 (7.62%) 6 (5.71%) 0.4795
Adjuvant therapy
Chemotherapy 13 (12.4%) 6 (5.71%) 0.108
Radiotherapy 26 (24.76%) 16 (15.24%) 0.068
Tumor size 3.74  1.86 5.20  2.66 0.001
Preoperative FEV1 2.45  0.720 2.38  0.67 0.180
a Other tumors included pulmonary sarcomas, adenosquamous carcinomas, etc.
Low-grade malignant tumors such as mucoepidermoid carcinomas, and adenoid cystic
carcinomas were excluded from the analysis.
FEV1, first second forced expiratory volume.
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Mortality and Morbidity
As shown in Table 2, the operative mortality was 1.0%
(1/105 patients) for the SL and 8.6% (8/105 patients) for the
PN group (p  0.0001). In the SL group, death occurred due
to ARDS. In the PN group, causes of death included ARDS
(n  6), pneumonia (n  1), and sudden cardiac arrest with
an undetermined cause (n  1). The rate and pattern of
postoperative morbidity was similar in both groups (33.4% in
SL group and 29.5% in PN group, p  0.376). The distribu-
tions of morbidities in two groups showed no significant
difference even when all of the morbidities were subdivided
into major and minor complications.
Survival and Recurrence
The overall 3-year survival rates were 71.4% for the SL
group and 41.8% for the PN group (p  0.0001). The overall
5-year survival rates were 58.4% for the SL group and 32.1%
for the PN group (p  0.0002) (Figure 1). The data showed
that patients in PN group had poorer survival than those in SL
group (p  0.0002, odd ratio of 3.14).
Locoregional recurrence pattern of the matched patients
was showed in Table 3. Although direct comparison of
recurrence pattern of two groups was not possible due to the
pair-match design of the analysis, the composition of locore-
gional and distant recurrence was similar in two groups.
Nevertheless, in 12 pairs having recurrence in both groups,
there was no significant difference in pattern of recurrence
(p 0.180), even though the number of included subject was
rather small to have statistical significance.
Functional Outcomes
Both the SL and the PN group had similar preoperative
lung function. The mean preoperative FEV1 for the patients
underwent PN was 2.38  0.67 liter compared with 2.45 
0.720 liter for the patients who underwent SL (p  0.18).
Additionally, for the entire patients who underwent SL, the
mean predicted post-PN FEV1 was 1.90  0.50 liter and the
mean actual postoperative FEV1 was 2.05 0.55 liter, which
was decreased by 18.5% compared with the preoperative
FEV1 and increased by 7.9% compared with predicted
post-PN FEV1. The correlation value between the predicted
and measured FEV1 was 0.93.
DISCUSSION
Sleeve resections have gained in popularity regardless
of the preoperative pulmonary function status of patients.1,4–6,10
The preservation of lung function is closely associated with
the quality of life and low cardiopulmonary morbidity. On the
other hand, the PN is associated with significant morbidity
and mortality, including ARDS, BPF, and the post-PN syn-
drome. In our series, the SL was performed in patients who
could have tolerated a PN, if only it was technically possible,
hence both the SL and PN groups had a similar preoperative
FEV1.
TABLE 2. Postoperative Morbidity and Mortality
Sleeve
Lobectomy
(n  157)
Pneumonectomy
(n  267) p
Operative mortality 1 (1.0%) 8 (8.6%) 0.0001
Operative morbidity 34 (33.4%) 31 (29.5%)
Major complication 9 (8.6%) 13 (12.4%)
ARDS 4 7
Bronchopleural fistula 4 5
Empyema
Bronchovascular fistula 1
Chylothorax 1
Minor complication 25 (23.8%) 18 (17.1%) 0.376
Pneumonia 2 2
Atelectasis 3
Vocal cord palsy 3 4
Mild bronchial stenosis 3
Prolonged air leak 7
Hemothorax 1
Atrial fibrillation 3 5
Wound infection 4 6
ARDS, acute respiratory distress syndrome.
FIGURE 1. Cumulative survival curves of patients.
TABLE 3. Recurrence Pattern After Sleeve Lobectomy and
Pneumonectomy
Sleeve
Lobectomy Pneumonectomy p
Total recurrence 32 (30.5%) 40 (38.1%) 0.180a
Locoregional 15 (14.3%) 17 (16.2%)
Bronchial anastomosis
or stump
2 3
Distant 12 (11.4%) 23 (21.9%)
a The comparison of recurrence pattern was conducted for only 12 pairs in which
recurrence was occurred in two groups.
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In recent reports, the SL has been performed in 3.4 to
13% of the patients diagnosed with a resectable lung can-
cer.1,11 In our series, the SL was performed in 8.5% of the
patients with lung cancer. Martin-Ucar et al.12 reported that
the increased use of bronchoplastic techniques decreased the
need for a PN. As surgical experience accumulates, centrally
located NSCLC may have a higher probability of being
treated by bronchoplastic surgery.
SL should achieve certain oncological, operative, and
functional requirements to be accepted as a standard proce-
dure. The results of recent studies suggest that the long-term
survival after SL is as favorable as that after PN, with a lower
mortality and better quality of life, mainly due to the preser-
vation of lung function.1,7,12,13 In addition, local tumor con-
trol, which is a major concern with bronchoplasty, has been
found to be acceptable.1–4,6,7
The major and minor complications were similar in
both the SL and the PN group (p  0.376) in our series. In
particular, there were no significant differences in complica-
tions related with bronchial anastomosis or bronchial stump
between the two groups. Nevertheless, the operative mortality
was significantly lower after the SL (1.0%) compared with
that after the PN (8.6%). Our results suggest that SL is a safer
operative procedure, when compared with PN, even though
bronchial anastomosis is performed.
The main reason for the hesitation in performing the SL
is the concern about local recurrence. The local recurrence
rate after SL ranges from 8 to 23%, whereas the local
recurrence after the PN is reported to be 10 to 14%.1,14 There
was no significant difference in recurrence pattern between
SL group and PN group in our study (p  0.180). These
results are consistent with other studies that showed a similar
local recurrence rate between SL and PN. In most recent
reports, the long-term survival after a SL, in stage I/II or
N0/N1 disease, was similar to that after a PN.1,5–7 Okada
et al.1 noted that the most important factor for survival after
a SL was the nodal status; the patients with N2 disease
showed poor survival compared with those with N0 and N1
disease. In our study, patients were stratified according to
pathologic substage from the design of the study. Consid-
ering that, it could be said that the patients in the SL group
had higher 5-year survival rate compared with those in the
PN group.
In a recent prospective study, Balduyck et al.15 reported
that patients who had a SL returned to their baseline quality
of life in less than 1 month after the surgery. By contrast, the
PN patients had decreased physical and functional endurance
during the first year of follow-up. Gaissert et al.4 reported that
the perfusion and ventilation of the reimplanted lung was
compatible with that of the predicted lung function after a SL.
In our study, the postoperative FEV1 after the sleeve resec-
tion was decreased by only 18.5% compared with the preop-
erative FEV1. These data show a complete recovery of the
reimplanted lung after a SL.
In conclusion, SL is a safe and effective operation in
the treatment of NSCLC. If anatomically feasible, SL is
recommended as a favorable alternative to PN in the patients
even with good pulmonary function.
REFERENCES
1. Okada M, Yamagishi H, Satake S, et al. Survival related to lymph node
involvement in lung cancer after sleeve lobectomy compared with
pneumonectomy. J Thorac Cardiovasc Surg 2000;119:814–819.
2. Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy:
optimal management strategy using decision analysis techniques. Ann
Thorac Surg 2003;76:1782–1788.
3. Icard Ph, Regnard JF, Guibert L, et al. Survival and prognostic factors in
patients undergoing parenchymal saving bronchoplastic operation for
primary lung cancer: a series of 110 consecutive cases. Eur J Cardio-
thorac Surg 1999;15:426–432.
4. Gaissert HA, Mathisen DJ, Moncure AC, et al. Survival and function
after sleeve lobectomy for lung cancer. J Thorac Cardiovasc Surg
1996;111:948–953.
5. Deslauriers J, Gregoire J, Jacques LF, et al. Sleeve lobectomy versus
pneumonectomy for lung cancer: a comparative analysis of survival and
sites or recurrences. Ann Thorac Surg 2004;77:1152–1156.
6. Fadel E, Yildizeli B, Chapelier AR, et al. Sleeve lobectomy for bron-
chogenic cancers: factors affecting survival. Ann Thorac Surg 2002;74:
851–858.
7. Ma Z, Dong A, Fan J, et al. Does sleeve lobectomy concomitant with or
without pulmonary artery reconstruction (double sleeve) have favorable
results for non-small cell lung cancer compared with pneumonectomy?
A meta-analysis. Eur J Cardiothorac Surg 2007;32:20–28.
8. Bernard A, Deschamps C, Allen MS, et al. Pneumonectomy for malig-
nant disease: factors affecting early morbidity and mortality. J Thorac
Cardiovasc Surg 2001;121:1076–1086.
9. Ferguson MK, Karrison T. Does pneumonectomy for lung cancer
adversely influence long-term survival? J Thorac Cardiovasc Surg
2000;119:440–448.
10. Takeda S, Maeda H, Koma H, et al. Comparison of surgical results after
pneumonectomy and sleeve lobectomy for non-small cell lung cancer.
Trends over time and 20-year institutional experience. Eur J Cardiotho-
rac Surg 2006;29:276–280.
11. Bagan P, Berna P, Pereira JCDN, et al. Sleeve lobectomy versus
pneumonectomy: tumor characteristics and comparative analysis of
feasibility and results. Ann Thorac Surg 2005;80:2046–2050.
12. Martin-Ucar AE, Chaudhuri N, Edwards JG, et al. Can pneumonectomy
for non-small cell lung cancer can be avoided? An audit of parenchymal
sparing lung surgery. Eur J Cardiothorac Surg 2002;21:601–605.
13. Terzi A, Lonardoni A, Falezza G, et al. Sleeve lobectomy for non-small
cell lung cancer and carcinoid: results in 160 cases. Eur J Cardiothorac
Surg 2002;21:888–893.
14. Mehran RJ, Deslauriers J, Piraux M, et al. Survival related to nodal
status after sleeve resection for lung cancer. J Thorac cardiovasc Surg
1994;107:576–583.
15. Balduyck B, Hendriks J, Lauwers P, et al. Quality of life after lung
cancer surgery: a prospective pilot study comparing bronchial sleeve
lobectomy with pneumonectomy. J Thorac Oncol 2008;3:604–608.
Park et al. Journal of Thoracic Oncology • Volume 5, Number 4, April 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer520
